The revised European League Against Rheumatism (EULAR) recommendations for RP in SSc patients (SSc-RP) treatment state that “calcium channel blockers should be used as first-line therapy and PDE-5 inhibitors in patients with SSc with severe RP and/or those who do not satisfactorily respond to calcium channel blockers” (Kowal-Bielecka et al., 2017). Here, PDE5A is linked to systemic sclerosis.